Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M402Revenue $M187Net Margin (%)-24.5Z-Score0.7
Enterprise Value $M365EPS $-0.7Operating Margin %-16.9F-Score4
P/E(ttm))0Cash Flow Per Share $0.7Pre-tax Margin (%)-23.3Higher ROA y-yY
Price/Book1.610-y EBITDA Growth Rate %0Quick Ratio2.0Cash flow > EarningsY
Price/Sales2.15-y EBITDA Growth Rate %0Current Ratio2.0Lower Leverage y-yN
Price/Cash Flow16.2y-y EBITDA Growth Rate %0ROA % (ttm)-9.3Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)0ROE % (ttm)-17.3Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M66.9ROI % (ttm)5.7Gross Margin Increase y-yY

Gurus Latest Trades with SPPI

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SPPIJohn Burbank 2012-12-31 Sold Out -0.13%$10.64 - $12.31
($11.39)
$ 6.01-90%Sold Out0
SPPIJoel Greenblatt 2012-12-31 Sold Out -0.02%$10.64 - $12.31
($11.39)
$ 6.01-90%Sold Out0
SPPIJohn Burbank 2012-09-30 Buy 0.13%$11.6 - $17.05
($13.85)
$ 6.01-130%New holding250,000
SPPIJoel Greenblatt 2012-09-30 Buy 0.02%$11.6 - $17.05
($13.85)
$ 6.01-130%New holding19,901
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SPPI is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


SPPI: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
MAIDA ANTHONY E IIIDirector 2013-03-05Sell5,000$11.5-47.74view
MAIDA ANTHONY E IIIDirector 2013-02-05Sell5,000$12.25-50.94view
MAIDA ANTHONY E IIIDirector 2013-01-02Sell5,000$11.42-47.37view
SHROTRIYA RAJESH C MDChairman, CEO & President 2012-12-31Sell378,343$11.29-46.77view
MAIDA ANTHONY E IIIDirector 2012-12-04Sell5,000$11.65-48.41view
Keller Joseph KennethEVP & COO 2012-11-12Buy10,000$10.95-45.11view
MAIDA ANTHONY E IIIDirector 2012-11-01Sell5,000$11.09-45.81view
SHROTRIYA RAJESH C MDChairman, CEO & President 2012-10-09Sell11,350$12.5-51.92view
MAIDA ANTHONY E IIIDirector 2012-10-02Sell5,000$11.8-49.07view
Scott Brett LActing CFO 2012-10-01Sell6,000$12-49.92view

Press Releases about SPPI :

    Quarterly/Annual Reports about SPPI:

    News about SPPI:

    Articles On GuruFocus.com
    http://seekingalpha. Aug 15 2012 
    Spectrum: Allos Acquisition Means Huge Upside Potential May 04 2012 
    5 Stocks Exceeding Expectations In 2012 Mar 31 2012 
    Was Gilead's Acquisition of Pharmasset a Dose of Bad Medicine? Mar 05 2012 
    Spectrum Pharmaceuticals Inc. Reports Operating Results (10-K) Mar 10 2011 
    Weekly CFO Buys Highlight: CNYD, PRWT, ANCB, SPPI, SPAX Jan 31 2011 
    Weekly CFO Buys Highlight: FUL, SPPI, GRF, BPAX Jan 25 2011 
    Weekly Top Insider Buys: NPBC, FUL, GAM, SHLM, SPPI Jan 24 2011 
    Spectrum Pharmaceuticals Inc. (SPPI) CFO Brett L Scott buys 4,000 Shares Jan 21 2011 
    Spectrum Pharmaceuticals Inc. Reports Operating Results (10-Q) Nov 04 2010 

    More From Other Websites
    SPECTRUM PHARMACEUTICALS INC Financials Mar 20 2015
    SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 13 2015
    Spectrum Pharma reports 4Q loss Mar 13 2015
    Spectrum Pharma reports 4Q loss Mar 13 2015
    Spectrum Pharmaceuticals Reports Robust Clinical Data and Strong 2014 Financial Results Mar 13 2015
    Q4 2014 Spectrum Pharmaceuticals Inc Earnings Release - Time Not Supplied Mar 13 2015
    Spectrum Pharmaceuticals Reports Robust Clinical Data and Strong 2014 Financial Results Mar 13 2015
    Four Oncology Key Opinion Leaders to Present at Spectrum Pharmaceuticals' Analyst Day on Friday,... Mar 11 2015
    Four Oncology Key Opinion Leaders to Present at Spectrum Pharmaceuticals’ Analyst Day on Friday,... Mar 11 2015
    Spectrum Pharmaceuticals' CE-melphalan Under Review - Analyst Blog Mar 10 2015
    Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Captisol-Enabled™ (Propylene... Mar 09 2015
    Spectrum Pharmaceuticals Announces FDA's Acceptance of NDA Filing for Captisol-Enabled™ (Propylene... Mar 09 2015
    Spectrum Pharmaceuticals In-Licenses Poziotinib, a Novel pan-HER Inhibitor With Clinical Activity in... Mar 04 2015
    Spectrum Pharmaceuticals In-Licenses Poziotinib, a Novel pan-HER Inhibitor With Clinical Activity in... Mar 04 2015
    Spectrum Pharmaceuticals (SPPI) Stock Plunges to One-Year Low on Court's Fusilev Patent Ruling Feb 23 2015
    BUZZ-U.S. STOCKS ON THE MOVE-Boeing, Dish, Valeant, Spectrum Pharma Feb 23 2015
    SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Regulation FD Disclosure Feb 23 2015
    Spectrum Pharma downgraded by ROTH Capital Feb 23 2015
    SPECTRUM PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers Feb 20 2015
    Spectrum Pharmaceuticals to Present Corporate Update at the 2015 RBC Capital Markets' Global... Feb 20 2015

    Add Notes, Comments

    If you want to ask a question, or report a bug, please create a support ticket.

    User Comments

    No comment yet
    Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
    GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
    Free 7-day Trial
    FEEDBACK